中国组织工程研究 ›› 2022, Vol. 26 ›› Issue (24): 3928-3936.doi: 10.12307/2022.578
• 干细胞综述 stem cell review • 上一篇
刘 超,曾昭穆,温稀超,吴文松,孙程圆,郑克彬
收稿日期:
2021-05-21
修回日期:
2021-05-24
接受日期:
2021-06-21
出版日期:
2022-08-28
发布日期:
2022-01-24
通讯作者:
郑克彬,博士,主任医师,河北大学附属医院神经外科,河北省保定市 071000
作者简介:
刘超,男,1996年生,福建省泉州市人,汉族,河北大学在读硕士,主要从事脑胶质瘤的基因治疗与临床研究。
基金资助:
Liu Chao, Zeng Zhaomu, Wen Xichao, Wu Wensong, Sun Chengyuan, Zheng Kebin
Received:
2021-05-21
Revised:
2021-05-24
Accepted:
2021-06-21
Online:
2022-08-28
Published:
2022-01-24
Contact:
Zheng Kebin, MD, Chief physician, Department of Neurosurgery, Affiliated Hospital of Hebei University, Baoding 071000, Hebei Province, China
About author:
Liu Chao, Master candidate, Department of Neurosurgery, Affiliated Hospital of Hebei University, Baoding 071000, Hebei Province, China
Supported by:
摘要:
文题释义:
神经胶质瘤:是一种中枢神经系统中侵袭能力强及恶性程度较高的肿瘤,临床上治疗神经胶质瘤主要采取手术联合放化疗的综合治疗方法,但是仍有90%的复发率。
外泌体:是最常见的细胞外囊泡类型,可作为蛋白质、RNA和其他生物活性分子的载体。外泌体在肿瘤发生和化疗或放疗耐药性中发挥着关键作用。
背景:恶性神经胶质瘤经过手术、放疗和化疗后,其预后仍然很差,因此阐明胶质瘤发生发展的分子机制,进一步探索可靠的生物标志物至关重要。非编码RNA在外泌体中富集且稳定,由于其在各种肿瘤的起始和进展中的调节功能而受到了广泛关注。
目的:文章就外泌体非编码RNA在胶质瘤中的研究和进展进行概述,介绍外泌体非编码RNA的生物来源,阐明其在胶质瘤中的生物学影响,寻找可靠的肿瘤标志物,以期为神经胶质瘤的诊断和治疗提供新的思路。
方法:以“Exosome,Extracellular vesicles,Noncoding RNA,Glioma,Molecule mechanism,Biomarkers”为英文检索词,在PubMed和Web of Science数据库中检索筛选出114篇文献进行归纳总结,文献内容主要涉及外泌体非编码RNA在胶质瘤中的肿瘤细胞增殖、侵袭和血管生成,以及外泌体非编码RNA在胶质瘤中的基因诊断和基因治疗等相关内容。
结果与结论:①外泌体非编码RNA在细胞间选择性包装、分泌和转移,参与肿瘤微环境中的细胞间通讯,并可调节胶质瘤的许多生物学行为,如增殖、侵袭、血管生成、免疫逃逸和治疗耐药性,在胶质瘤的发生发展中起着重要作用。②外泌体包含多种功能分子,可以反映整个肿瘤复杂的异质性。③外泌体具有较高的特异性和灵敏度,并且非常稳定,在几乎所有类型的体液中都很容易获得,这些因素使外泌体成为最有潜力的生物标记物,这为未来诊断胶质瘤提供了很大帮助。④外泌体是天然且无毒性的,与质膜的构造相当类似,可将其作为许多治疗性药物的治疗载体,携带多种生物活性分子并能轻易跨越血脑屏障,通过外泌体来开发靶向抗癌药物,既能突破血脑屏障,还能避免人体的免疫排斥反应。⑤外泌体与靶细胞结合具有特定的靶向性,这些优势极大提升了外泌体应用在胶质瘤生物靶向治疗的可行性,但其在临床应用中还面临着一些困难,如外泌体的分选难度大,外泌体非编码RNA的含量有限,以及如何让外泌体精确到达肿瘤部位等。⑥随着外泌体非编码RNA在胶质瘤中研究的不断深入,未来将为攻克胶质瘤这一难题提供新的路径。
https://orcid.org/0000-0001-6994-8703 (刘超)
中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程
中图分类号:
刘 超, 曾昭穆, 温稀超, 吴文松, 孙程圆, 郑克彬. 外泌体非编码RNA在胶质瘤发生发展中的作用及其临床应用前景[J]. 中国组织工程研究, 2022, 26(24): 3928-3936.
Liu Chao, Zeng Zhaomu, Wen Xichao, Wu Wensong, Sun Chengyuan, Zheng Kebin. Role and clinical application prospects of exosomal non-coding RNAs in the occurrence and development of glioma[J]. Chinese Journal of Tissue Engineering Research, 2022, 26(24): 3928-3936.
[1] MOLINARO AM, TAYLOR JW, WIENCKE JK, et al. Genetic and molecular epidemiology of adult diffuse glioma. Nat Rev Neurol. 2019;15(7):405-417. [2] STUPP R, MASON WP, VAN DEN BENT MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. [3] ALIFIERIS C, TRAFALIS DT. Glioblastoma multiforme: pathogenesis and treatment. Pharmacol Ther. 2015;152:63-82. [4] QUAIL DF, JOYCE JA. The microenvironmental landscape of brain tumors. Cancer Cell. 2017;31(3):326-341. [5] GODLEWSKI J, KRICHEVSKY AM, JOHNSON MD, et al. Belonging to a network--microRNAs, extracellular vesicles, and the glioblastoma microenvironment. Neuro Oncol. 2015;17(5):652-662. [6] BIAN EB, CHEN EF, XU YD, et al. Exosomal lncRNA‑ATB activates astrocytes that promote glioma cell invasion. Int J Oncol. 2019;54(2):713-721. [7] ELLERT-MIKLASZEWSKA A, PASIERBINSKA M, POLESZAK K, et al. Molecular interactions between tumor and its microenvironment in malignant gliomas. Postepy Biochem. 2018;64(2):129-140. [8] CHIODONI C, DI MARTINO MT, ZAZZERONI F, et al. Cell communication and signaling: how to turn bad language into positive one. J Exp Clin Cancer Res. 2019;38(1):128. [9] RAPOSO G, STAHL PD. Extracellular vesicles: a new communication paradigm? Nat Rev Mol Cell Biol. 2019;20(9):509-510. [10] TKACH M, THÉRY C. Communication by extracellular vesicles: where we are and where we need to go. Cell. 2016;164(6):1226-1232. [11] XIE Y, DANG W, ZHANG S, et al. The role of exosomal noncoding RNAs in cancer. Mol Cancer. 2019;18(1):37. [12] JIANG L, GU Y, DU Y, et al. Exosomes: diagnostic biomarkers and therapeutic delivery vehicles for cancer. Mol Pharm. 2019;16(8):3333-3349. [13] VAN NIEL G, D’ANGELO G, RAPOSO G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19(4):213-228. [14] SUN Z, YANG S, ZHOU Q, et al. Emerging role of exosome-derived long non-coding RNAs in tumor microenvironment. Mol Cancer. 2018;17(1):82. [15] HURLEY JH. ESCRT complexes and the biogenesis of multivesicular bodies. Curr Opin Cell Biol. 2008;20(1):4-11. [16] BAIETTI MF, ZHANG Z, MORTIER E, et al. yndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat Cell Biol. 2012;14(7):677-685. [17] STUFFERS S, SEM WEGNER C, STENMARK H, et al. Multivesicular endosome biogenesis in the absence of ESCRTs. Traffic. 2009;10(7):925-937. [18] CHAIROUNGDUA A, SMITH DL, POCHARD P, et al. Exosome release of β-catenin: a novel mechanism that antagonizes Wnt signaling. J Cell Biol. 2010;190(6): 1079-1091. [19] OSTROWSKI M, CARMO NB, KRUMEICH S, et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol. 2010;12(1): 19-30. [20] MULCAHY LA, PINK RC, CARTER DR. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles. 2014. doi: 10.3402/jev.v3.24641. [21] GUO X, QIU W, WANG J, et al. Glioma exosomes mediate the expansion and function of myeloid-derived suppressor cells through microRNA-29a/Hbp1 and microRNA-92a/Prkar1a pathways. Int J Cancer. 2019;144(12):3111-3126. [22] COLOMBO M, RAPOSO G, THÉRY C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255-289. [23] CHISTIAKOV DA, CHEKHONIN VP. Extracellular vesicles shed by glioma cells: pathogenic role and clinical value. Tumour Biol. 2014;35(9):8425-8438. [24] VAN DER VOS KE, ABELS ER, ZHANG X, et al. Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain. Neuro Oncol. 2016;18(1):58-69. [25] KATAKOWSKI M, BULLER B, ZHENG X, et al. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett. 2013;335(1): 201-204. [26] DENG SZ, LAI MF, LI YP, et al. Human marrow stromal cells secrete microRNA-375-containing exosomes to regulate glioma progression. Cancer Gene Ther. 2020;27(3-4):203-215. [27] YU L, GUI S, LIU Y, et al. Exosomes derived from microRNA-199a-overexpressing mesenchymal stem cells inhibit glioma progression by down-regulating AGAP2. Aging (Albany NY). 2019;11(15):5300-5318. [28] SHARIF S, GHAHREMANI MH, SOLEIMANI M. Delivery of exogenous mir-124 to glioblastoma multiform cells by wharton’s jelly mesenchymal stem cells decreases cell proliferation and migration, and confers chemosensitivity. Stem Cell Rev Rep. 2018;14(2):236-246. [29] ZHAO M, XU J, ZHONG S, et al. Expression profiles and potential functions of circular RNAs in extracellular vesicles isolated from radioresistant glioma cells. Oncol Rep. 2019;41(3):1893-1900. [30] ZHANG X, ZHANG X, HU S, et al. Identification of miRNA-7 by genome-wide analysis as a critical sensitizer for TRAIL-induced apoptosis in glioblastoma cells. Nucleic Acids Res. 2017;45(10):5930-5944. [31] LANG FM, HOSSAIN A, GUMIN J, et al. Mesenchymal stem cells as natural biofactories for exosomes carrying miR-124a in the treatment of gliomas. Neuro Oncol. 2018;20(3):380-390. [32] JEPPESEN DK, FENIX AM, FRANKLIN JL, et al. Reassessment of exosome composition. Cell. 2019;177(2):428-445. [33] KIM KM, ABDELMOHSEN K, MUSTAPIC M, et al. RNA in extracellular vesicles. Wiley Interdiscip Rev RNA. 2017;8(4):10. [34] Pegtel DM, Gould SJ. Exosomes. Annu Rev Biochem. 2019;88:487-514. [35] NIE JH, LI TX, ZHANG XQ, et al. Roles of non-coding rnas in normal human brain development, brain tumor, and neuropsychiatric disorders. Noncoding RNA. 2019;5(2):36. [36] ZHU L, LIU X, PU W, et al. tRNA-derived small non-coding RNAs in human disease. Cancer Lett. 2018;419:1-7. [37] ZHU L, LI J, GONG Y, et al. Exosomal tRNA-derived small RNA as a promising biomarker for cancer diagnosis. Mol Cancer. 2019;18(1):74. [38] LI B, HONG J, HONG M, et al. piRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment. Oncogene. 2019;38(26): 5227-5238. [39] PENG Y, CROCE CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016;1:15004. [40] MACFARLANE LA, MURPHY PR. MicroRNA: biogenesis, function and role in cancer. Curr Genomics. 2010;11(7):537-561. [41] KOZOMARA A, BIRGAOANU M, GRIFFITHS-JONES S. miRBase: from microRNA sequences to function. Nucleic Acids Res. 2019;47(1):155-162. [42] SAADATPOUR L, FADAEE E, FADAEI S, et al. Glioblastoma:exosome and microRNA as novel diagnosis biomarkers. Cancer Gene Ther. 2016;23(12):415-418. [43] PENG Z, LIU C, WU M. New insights into long noncoding RNAs and their roles in glioma. Mol Cancer. 2018;17(1):61. [44] QUINN JJ, CHANG HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47-62. [45] KOPP F, MENDELL JT. Functional classification and experimental dissection of long noncoding RNAs. Cell 2018;172(3):393-407. [46] GOU Q, GAO L, NIE X, et al. Long Noncoding RNA AB074169 Inhibits Cell Proliferation via Modulation of KHSRP-Mediated CDKN1a Expression in Papillary Thyroid Carcinoma. Cancer Res. 2018;78(15):4163-4174. [47] WANG M, ZHOU L, YU F, et al. The functional roles of exosomal long non-coding RNAs in cancer. Cell Mol Life Sci. 2019;76(11):2059-2076. [48] DAI X, LIAO K, ZHUANG Z, et al. AHIF promotes glioblastoma progression and radioresistance via exosomes. Int J Oncol. 2019;54(1):261-270. [49] MA X, LI Z, LI T, et al. Long non-coding RNA HOTAIR enhances angiogenesis by induction of VEGFA expression in glioma cells and transmission to endothelial cells via glioma cell derived-extracellular vesicles. Am J Transl Res. 2017;9(11):5012-5021. [50] CHEN LL. The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 2016;17(4):205-211. [51] SHANG Q, YANG Z, JIA R, et al. The novel roles of circRNAs in human cancer. Mol Cancer. 2019;18(1):6. [52] LI X, YANG L, CHEN LL. The biogenesis, functions, and challenges of circular RNAs. Mol Cell. 2018;71(3):428-442. [53] RYBAK-WOLF A, STOTTMEISTER C, GLAŽAR P, et al. Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Mol Cell. 2015;58(5):870-885. [54] ZHANG M, ZHAO K, XU X, et al. A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma. Nat Commun. 2018;9(1):4475. [55] LIU J, ZHAO K, HUANG N, et al. Circular RNAs and human glioma. Cancer Biol Med. 2019;16(1):11-23. [56] HAO Z, HU S, LIU Z, et al. Circular RNAs: functions and prospects in glioma. J Mol Neurosci. 2019;67(1):72-81. [57] LI Y, ZHENG Q, BAO C, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 2015;25(8):981-984. [58] WANG Y, LIU J, MA J, et al. Exosomal circRNAs: biogenesis, effect and application in human diseases. Mol Cancer. 2019;18(1):116. [59] LASDA E, PARKER R. Circular RNAs co-precipitate with extracellular vesicles: a possible mechanism for circRNA clearance. PLoS One. 2016;11(2):e0148407. [60] TAN S, GOU Q, PU W, et al. Circular RNA F-circEA produced from EML4-ALK fusion gene as a novel liquid biopsy biomarker for non-small cell lung cancer. Cell Res. 2018;28(6):693-695. [61] ROOJ AK, MINEO M, GODLEWSKI J. MicroRNA and extracellular vesicles in glioblastoma:small but powerful. Brain Tumor Pathol. 2016;33(2):77-88. [62] XIE Q, MITTAL S, BERENS ME. Targeting adaptive glioblastoma:an overview of proliferation and invasion. Neuro Oncol. 2014;16(12):1575-1584. [63] CHEN X, YANG F, ZHANG T, et al. MiR-9 promotes tumorigenesis and angiogenesis and is activated by MYC and OCT4 in human glioma. J Exp Clin Cancer Res. 2019;38(1):99. [64] FAREH M, ALMAIRAC F, TURCHI L, et al. Cell-based therapy using miR-302-367 expressing cells represses glioblastoma growth. Cell Death Dis. 2017;8(3): e2713. [65] NOHATA N, HANAZAWA T, ENOKIDA H, et al. microRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers. Oncotarget. 2012;3(1):9-21. [66] BRONISZ A, WANG Y, NOWICKI MO, et al. Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1. Cancer Res. 2014;74(3):738-750. [67] CAI Q, ZHU A, GONG L. Exosomes of glioma cells deliver miR-148a to promote proliferation and metastasis of glioblastoma via targeting CADM1. Bull Cancer. 2018;105(7-8):643-651. [68] ONISHI M, ICHIKAWA T, KUROZUMI K, et al. Angiogenesis and invasion in glioma. Brain Tumor Pathol. 2011;28(1):13-24. [69] WANG Y, WANG L, CHEN C, et al. New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications. Mol Cancer. 2018; 17(1):22. [70] YADAV L, PURI N, RASTOGI V, et al. Tumour Angiogenesis and Angiogenic Inhibitors: a Review. J Clin Diagn Res. 2015;9(6):Xe01-Xe05. [71] VALLÉE A, GUILLEVIN R, VALLÉE JN. Vasculogenesis and angiogenesis initiation under normoxic conditions through Wnt/β-catenin pathway in gliomas. Rev Neurosci. 2018;29(1):71-91. [72] WANG ZF, LIAO F, WU H, et al. Glioma stem cells-derived exosomal miR-26a promotes angiogenesis of microvessel endothelial cells in glioma. J Exp Clin Cancer Res. 2019;38(1):201. [73] LANG HL, HU GW, CHEN Y, et al. Glioma cells promote angiogenesis through the release of exosomes containing long non-coding RNA POU3F3. Eur Rev Med Pharmacol Sci. 2017;21(5):959-972. [74] ABELS ER, MAAS SLN, NIELAND L, et al. Glioblastoma-associated microglia reprogramming is mediated by functional transfer of extracellular miR-21. Cell Rep. 2019;28(12):3105-3119. [75] SUN X, MA X, WANG J, et al. Glioma stem cells-derived exosomes promote the angiogenic ability of endothelial cells through miR-21/VEGF signal. Oncotarget. 2017;8(22):36137-36148. [76] PASTORI C, KAPRANOV P, PENAS C, et al. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation. Proc Natl Acad Sci U S A. 2015;112(27):8326-8331. [77] LANG HL, HU GW, ZHANG B, et al. Glioma cells enhance angiogenesis and inhibit endothelial cell apoptosis through the release of exosomes that contain long non-coding RNA CCAT2. Oncol Rep. 2017;38(2):785-798. [78] LATHIA JD, GALLAGHER J, MYERS JT, et al. Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PLoS One. 2011;6(9):e24807. [79] JHAVERI N, CHEN TC, HOFMAN FM. Tumor vasculature and glioma stem cells: contributions to glioma progression. Cancer Lett. 2016;380(2):545-551. [80] GIERYNG A, PSZCZOLKOWSKA D, WALENTYNOWICZ KA, et al. Immune microenvironment of gliomas. Lab Invest. 2017;97(5):498-518. [81] CHEN Z, HAMBARDZUMYAN D. Immune microenvironment in glioblastoma subtypes. Front Immunol. 2018;9:1004. [82] LOCARNO CV, SIMONELLI M, CARENZA C, et al. Role of myeloid cells in the immunosuppressive microenvironment in gliomas. Immunobiology. 2020; 225(1):151853. [83] QIAN M, WANG S, GUO X, et al. Hypoxic glioma-derived exosomes deliver microRNA-1246 to induce M2 macrophage polarization by targeting TERF2IP via the STAT3 and NF-κB pathways. Oncogene. 2020;39(2):428-442. [84] GUO X, QIU W, LIU Q, et al. Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten Pathways. Oncogene. 2018;37(31):4239-4259. [85] QAZI MA, VORA P, VENUGOPAL C, et al. Intratumoral heterogeneity:pathways to treatment resistance and relapse in human glioblastoma. Ann Oncol. 2017; 28(7):1448-1456. [86] BAO S, WU Q, MCLENDON RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444 (7120):756-760. [87] YANG JK, YANG JP, TONG J, et al. Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma. J Neurooncol. 2017;131(2):255-265. [88] FAN Q, YANG L, ZHANG X, et al. The emerging role of exosome-derived non-coding RNAs in cancer biology. Cancer Lett. 2018;414:107-115. [89] YOSHIMOTO K, MIZOGUCHI M, HATA N, et al. Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma. Front Oncol. 2012;2:186. [90] ZENG A, WEI Z, YAN W, et al. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. Cancer Lett. 2018;436:10-21. [91] ZHANG Z, YIN J, LU C, et al. Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma. J Exp Clin Cancer Res. 2019;38(1):166. [92] YUE X, LAN F, XIA T. Hypoxic glioma cell-secreted exosomal miR-301a activates wnt/β-catenin signaling and promotes radiation resistance by targeting TCEAL7. Mol Ther. 2019;27(11):1939-1949. [93] ZHAO M, XU J, ZHONG S, et al. Expression profiles and potential functions of circular RNAs in extracellular vesicles isolated from radioresistant glioma cells. Oncol Rep. 2019;41(3):1893-1900. [94] SMIRNIOTOPOULOS JG, MURPHY FM, RUSHING EJ, et al. Patterns of contrast enhancement in the brain and meninges. Radiographics. 2007;27(2):525-551. [95] RADBRUCH A, FLADT J, KICKINGEREDER P, et al. Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence. Neuro Oncol. 2015;17(1):151-159. [96] SORENSEN AG, BATCHELOR TT, WEN PY, et al. Response criteria for glioma, Nature clinical practice. Nat Clin Pract Oncol. 2008;5(11):634-644. [97] WESTPHAL M, LAMSZUS K. Circulating biomarkers for gliomas. Nat Rev Neurol. 2015;11(10):556-566. [98] BULLOCK MD, SILVA AM, KANLIKILICER-UNALDI P, et al. Exosomal non-coding rnas: diagnostic, prognostic and therapeutic applications in cancer. Noncoding RNA. 2015;1(1):53-68. [99] CECH TR, STEITZ JA. The noncoding RNA revolution-trashing old rules to forge new ones. Cell. 2014;157(1):77-94. [100] MATSUMOTO J, STEWART T, BANKS WA, et al. The transport mechanism of extracellular vesicles at the blood-brain barrier. Curr Pharm Des. 2017; 23(40):6206-6214. [101] SANTANGELO A, IMBRUCÈ P, GARDENGHI B, et al. A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker. J Neurooncol. 2018;136(1):51-62. [102] LAN F, QING Q, PAN Q, et al. Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma. Cell Oncol (Dordr). 2018;41(1):25-33. [103] SHAO N, XUE L, WANG R, et al. miR-454-3p is an exosomal biomarker and functions as a tumor suppressor in glioma. Mol Cancer Ther. 2019;18(2):459-469. [104] TAN SK, PASTORI C, PENAS C, et al. Serum long noncoding RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme. Mol Cancer. 2018;17(1):74. [105] MANTEROLA L, GURUCEAGA E, GÁLLEGO PÉREZ-LARRAYA J, et al. A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro Oncol. 2014;16(4) 520-527. [106] SHI R, WANG PY, LI XY, et al. Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients. Oncotarget. 2015;6(29):26971-2681. [107] CHAN JA, KRICHEVSKY AM, KOSIK KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005;65(14):6029-6033. [108] AKERS JC, RAMAKRISHNAN V, KIM R, et al. MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. PLoS One. 2013;8(10):e78115. [109] H Rashed M, Bayraktar E, K Helal G, et al. Exosomes: from garbage bins to promising therapeutic targets. Int J Mol Sci. 2017;18(3):538. [110] MARLEAU AM, CHEN CS, JOYCE JA, et al. Exosome removal as a therapeutic adjuvant in cancer. J Transl Med. 2012;10:134. [111] TULLIS RH, DUFFIN RP, HANDLEY HH, et al. Reduction of hepatitis C virus using lectin affinity plasmapheresis in dialysis patients. Blood Purif. 2009;27(1):64-69. [112] NAIR KGS, RAMAIYAN V, SUKUMARAN SK. Enhancement of drug permeability across blood brain barrier using nanoparticles in meningitis. Inflammopharmacology. 2018;26(3):675-684. [113] LAI CP, MARDINI O, ERICSSON M, et al. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. ACS Nano. 2014;8(1):483-494. [114] MUNOZ JL, BLISS SA, GRECO SJ, et al. Delivery of functional anti-mir-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol Ther Nucleic Acids. 2013;2(10) e126. |
[1] | 唐文静, 伍思源, 杨 晨, 陶 希. 炎症反应与卒中后抑郁[J]. 中国组织工程研究, 2022, 26(8): 1278-1285. |
[2] | 郭 嘉, 丁琼桦, 刘 泽, 吕思懿, 周泉程, 高玉花, 白春雨. 间充质干细胞来源外泌体的生物学特性及免疫调控作用[J]. 中国组织工程研究, 2022, 26(7): 1093-1101. |
[3] | 吴玮玥, 郭晓东, 包崇云. 工程化外泌体在骨修复再生中的应用[J]. 中国组织工程研究, 2022, 26(7): 1102-1106. |
[4] | 周洪琴, 吴丹丹, 杨 琨, 刘 琪. 传递特定miRNA的外泌体可调控成骨并促进成血管[J]. 中国组织工程研究, 2022, 26(7): 1107-1112. |
[5] | 张璟琳, 冷 敏, 朱博恒, 汪 虹. 干细胞源外泌体促进糖尿病创面愈合的机制及应用[J]. 中国组织工程研究, 2022, 26(7): 1113-1118. |
[6] | 胡 伟, 谢兴奇, 屠冠军. 骨髓间充质干细胞来源外泌体改善脊髓损伤后血脊髓屏障的完整性[J]. 中国组织工程研究, 2022, 26(7): 992-998. |
[7] | 高俞锦, 彭双麟, 马治超, 陆 诗, 曹花月, 王 浪, 肖金刚. 糖尿病骨质疏松症模型小鼠脂肪干细胞的成骨能力[J]. 中国组织工程研究, 2022, 26(7): 999-1004. |
[8] | 陈 娜, 王晓含, 张运克. 间充质干细胞对衰老相关性缺血性卒中的作用及机制[J]. 中国组织工程研究, 2022, 26(24): 3914-3920. |
[9] | 王 为, 汤翔宇, 易智谦, 刘朝旭. 骨关节炎诱导软骨细胞凋亡和细胞外基质降解的机制[J]. 中国组织工程研究, 2022, 26(20): 3133-3140. |
[10] | 章晓云, 李华南, 陈 锋, 柴 源, 甘 斌, 李 松, 陈丁鹏. 网络药理学结合分子对接技术揭示桂枝芍药知母汤治疗痛风性关节炎的潜在分子机制[J]. 中国组织工程研究, 2022, 26(2): 245-252. |
[11] | 刘晓鹏, 张思森. 心搏骤停后血液生物标志物对于脑损伤的预测价值[J]. 中国组织工程研究, 2022, 26(2): 302-307. |
[12] | 单政铭, 陶述春, 胡春梅, 张治元, 丁一楠, 何梦铖, 唐秋莎. 人脐带间充质干细胞来源外泌体的提取、鉴定和蛋白组学分析[J]. 中国组织工程研究, 2022, 26(19): 3036-3042. |
[13] | 王伟伟, 欧志学, 章晓云, 李时斌, 周 毅, 李 统. 外泌体在激素性股骨头坏死修复信号交流网络中的调控机制[J]. 中国组织工程研究, 2022, 26(19): 3056-3064. |
[14] | 顾 霞, 王平义, 赵万花, 林语诗, 李一梅, 李文华. 外泌体介导低氧相关信号通路在疾病发生发展中的重要作用[J]. 中国组织工程研究, 2022, 26(19): 3065-3070. |
[15] | 白佳萌, 刘光伟, 谢 露, 毛垚耀, 何惠昌, 王春景. 间充质干细胞及其外泌体在肝再生领域的应用[J]. 中国组织工程研究, 2022, 26(19): 3071-3077. |
1.4 数据的提取 首先查看所有文章的标题及摘要,不能判断文献质量的则阅读全文,剔除重复文献,文献内容包括关于外泌体ncRNAs在胶质瘤中的研究进展。最终共纳入114篇英文文献[1-114],见图1。
文题释义:
神经胶质瘤:是一种中枢神经系统中侵袭能力强及恶性程度较高的肿瘤,临床上治疗神经胶质瘤主要采取手术联合放化疗的综合治疗方法,但是仍有90%的复发率。
外泌体:是最常见的细胞外囊泡类型,可作为蛋白质、RNA和其他生物活性分子的载体。外泌体在肿瘤发生和化疗或放疗耐药性中发挥着关键作用。
中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程
恶性神经胶质瘤是最常见和致命的中枢神经系统肿瘤类型。即使经过手术、放疗和化疗,胶质瘤的预后仍然很差,因此阐明胶质瘤发生发展的分子机制,进一步探索可靠的生物标志物至关重要。外泌体是一种新型的细胞间通讯方式,通过传递各种生物活性分子,包括蛋白质、脂质和RNA,并参与肿瘤的发生和发展。文章就外泌体非编码RNA在胶质瘤中的研究和进展做一篇综述。
中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||